The Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market size is estimated at USD 0.87 billion in 2022. It is expected to reach USD 2.35 billion by 2027, growing at a CAGR of 22.11% during the forecast period.
Nuclear medicine falls under the field of Molecular Imaging, which involves using a minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
The increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand for SPECT and PET applications, and the growing public awareness for healthcare are fuelling the growth of the Radiopharmaceuticals market. The integration of X-ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging. It is considered to be a driving factor for the growth of the market. However, a strict regulatory framework poses a significant hurdle to translational research, and clinical investigations and reimbursement issues are blocking the growth of the Radiopharmaceuticals market. Besides, the short half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures also restrain the Middle-East & Africa nuclear medicine market.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes and is expected to have a market share of 90 % of the radiopharmaceuticals market, while therapeutic radioisotopes contribute 10% of the market. Based on the type of radioisotopes, the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82), and others. F-18 FDG tracers mostly contribute to the F-18 market, though it is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring the high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease is the most promising indication for the future PET radioisotopes market.
This research report on the MEA nuclear medicine market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
KEY MARKET PLAYERS:
A few prominent companies operating in the MEA nuclear medicine market analyzed in this report are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p. A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Diagnostic Radioisotopes
5.1.1.1 SPECT
5.1.1.1.1 Technetium-99m
5.1.1.1.2 Thallium-201
5.1.1.1.3 Gallium-67
5.1.1.1.4 Iodine-23
5.1.1.1.5 Others
5.1.1.2 PET
5.1.1.2.1 Fluorine-18
5.1.1.2.2 Rubidium-82
5.1.1.2.3 Others
5.1.2 Therapeutic Radioisotopes
5.1.2.1 Beta Emitters
5.1.2.1.1 Iodine-131
5.1.2.1.2 Yttrium-90
5.1.2.1.3 Samarium-153
5.1.2.1.4 Rhenium-186
5.1.2.1.5 Lutetium-177
5.1.2.2 Alpha Emitters
5.1.2.2.1 Radium-223
5.1.2.3 Brachytherapy
5.1.2.3.1 Cesium-131
5.1.2.3.2 Iodine-125
5.1.2.3.3 Palladium-103
5.1.2.3.4 Iridium-192
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.1 UAE
6.2 Saudi Arabia
6.3 Israel
6.4 South Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hologic Inc.
8.3 Segami Corporation
8.4 Positron Corporation
8.5 Bracco Imaging S.P.A
8.6 Naviscan Inc.
8.7 Bayer Healthcare
8.8 Lantheus Medical Imaging Inc.
8.9 IBA Molecular Imaging
8.10 Medix Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.